This in-depth review of modern circulating tumor DNA assays highlights its proven clinical value in residual disease detection and therapy response monitoring, while widespread adoption remains limited by challenges in defining sensitivity thresholds, false negatives, cost, and seamless clinical integration. | Landon, Nat Med 2025
